ArticleFrontiers in pediatrics2022
Prevention of malaria in pregnancy: The threat of sulfadoxine-pyrimethamine resistance.
Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Indole-based hybrids target both asexual parasites and gametocytes ofAntimicrobial agents and chemotherapy · 2026Article
- Prevalence ofPathogens (Basel, Switzerland) · 2026Article
- Modelling the Cost-Effectiveness of a Placental Malaria Vaccine in Sub-Saharan Africa.Vaccines · 2026Article
- Malaria: a review on its current epidemiological status and management strategies.Malaria journal · 2026Review
- Improving malaria chemoprevention coverage in pregnancy: Surveying stakeholder preferences for new product profiles and community-delivery approaches across five African countries.PLOS global public health · 2026Article
- Maternal and household risk factors for malaria in pregnancy and low birthweight: a prospective cohort study from Uganda.Malaria journal · 2025Article
- Polymorphism of the dihydropteroate synthase resistance gene of Plasmodium falciparum in three hospitals in Mbouda, Western Cameroon.Tropical diseases, travel medicine and vaccines · 2025Article
- Advancing malaria treatment with magnetic and mesoporous silica nanoparticles loaded with sulfadoxine-pyrimethamine: a review.Discover nano · 2025Review
- Maternal and household risk factors for malaria in pregnancy and low birthweight: a prospective cohort study from Uganda.Research square · 2025Article
- Acceptability of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine plus dihydroartemisinin-piperaquine in Papua New Guinea: a qualitative study.Malaria journal · 2025Article
- Associations between prenatal malaria exposure, maternal antibodies at birth, and malaria susceptibility during the first year of life in Burkina Faso.Infection and immunity · 2023Article
- Perceptions of sulphadoxine-pyrimethamine use among pregnant women in sub-Saharan Africa: a scoping review.MalariaWorld journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria infection in pregnancy can lead to adverse outcomes for both the pregnant person and fetus. The administration of intermittent preventative therapy (IPTp) with sulfadoxine-pyrimethamine (SP) during pregnancy (IPTp-SP) improves outcomes, including severe maternal anemia, placental malaria infection, and low infant birth weight. The WHO recommends IPTp-SP for pregnant individuals living in areas of moderate or high malaria transmission in Africa. The current regimen consists of two or more doses of SP starting as early as possible in the second trimester, at least 1 month apart. Unfortunately, rising
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.